Investors

For a comprehensive breakdown of all investment particulars, please email info@apexlabs.com.

The APEX Advantage

  • 1

    Unmatched Team

    Decades of healthcare, clinical and pharmaceutical experience, executing 415 clinical trials, bringing 83 drugs to market in 70 countries with representation from the Veteran community in the C-suite and past corporate experience with Johnson & Johnson, Roche, GSK, Lilly, McKesson, Tilay, Sharp, and Canaccord.

  • 2

    First Mover in Take Home Psilocybin

    APEX is the first to launch and dose a take home microdose psilocybin clinical trial, with the largest of its kind authorized and beginning recruitment Q3 2024.

  • 3

    8-Year Data Exclusivity

    Following first Canadian commercial approval, APEX drug assets will have data protection for 8 years.


Revenue Model

1

Conditional Approval

Following Canadian phase 2b study completion with demonstrated outcomes, APEX will challenge regulatory agencies for pre-phase 3 conditional approval expanding towards full commercial approval.

2

Full Commercial Approval

Following or in lieu of conditional approval, secure DIN following phase 3 studies for APEX-52 take home microdose drug asset and APEX-90 macrodose drug asset achieving regulatory authorization in Canada, USA, Europe and Australia for broad commercial sales.